Cribb, Alastair E., et al. “Further Investigations of the Role of Acetylation in Sulphonamide Hypersensitivity Reactions”. Biomarkers, vol. 1, no. 4, 1996, pp. 267-72, https://doi.org/10.3109/13547509609079367.

Genre

  • Journal Article
Contributors
Author: Cribb, Alastair E.
Author: Nuss, C. E.
Author: Spielberg, S. P.
Author: Grant, D. M.
Date Issued
1996
Abstract

Sulphonamide hypersensitivity reactions are believed to be mediated through reactive intermediates derived from oxidation of the para-amino group to form sulphonamide hydroxylamines. Sulphamethoxazole hydroxylamine (SMX-HA) can be acetylated by N-acetyltransferase (NAT) enzymes to form an acetoxy metabolite (acetoxySMX). In the current studies, acetoxySMX was found to be not toxic over the concentration range of 0 to 500 mu M towards a human lymphoblastoid cell line (RPMI 1788) or a human hepatoma cell line (HepG2). Further, transient expression of NAT1 in COS-1 cells or stable transfection of NAT1 and NAT2 in HepG2 cells did not alter the toxicity of SMX-HA in vitro. The activity of NAT1 in isolated mononuclear leucocytes (a reflection of systemic NAT1 activity) determined with para-aminobenzoic acid as a substrate was not different between controls (n = 11) or patients with a known hypersensitivity reaction (n = 5) (4.1 +/- 1.2 nmol min(-1) mg(-1) vs 5.7 +/- 1.4 nmol min(-1) mg(-1)). Thus, acetoxySMX is unlikely to play a significant role in mediating SMX hypersensitivity reactions and a constitutive deficiency in NAT1 activity is not a common finding in patients susceptible to SMX hypersensitivity reactions.

Note

UNIV PRINCE EDWARD ISL,ATLANTIC VET COLL,DEPT ANAT & PHYSIOL,CHARLOTTETOWN,PE C1A 4P3,CANADA. MERCK RES LABS,W POINT,PA 19486. HOSP SICK CHILDREN,DIV CLIN PHARMACOL & TOXICOL,TORONTO,ON M5G 1X8,CANADA.

LONDON; ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE

TAYLOR & FRANCIS LTD

PT: J; CR: CHAO ES, 1988, CELL BIOL TOXICOL, V4, P1 CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900 CRIBB AE, 1991, J PHARMACOL EXP THER, V251, P1241 CRIBB AE, 1993, BIOCHEM PHARMACOL, V45, P1277 CRIBB AE, 1996, ADVERSE DRUG REACT T, V15, P9 CRIBB AE, 1996, CHEM RES TOXICOL, V9, P500 DUPRET JM, 1992, J BIOL CHEM, V267, P7381 KEARNS GL, 1994, J PEDIATR, V125, P805 LEE BL, 1994, CLIN PHARMACOL THER, V56, P184 NAKAMURA H, 1995, J PHARMACOL EXP THER, V274, P1099 PONSODA X, 1991, J TISSUE CULTURE MET, V13, P21 RIEDER MJ, 1989, ANN INTERN MED, V110, P286 RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13 RILEY RJ, 1991, BIOCHEM PHARMACOL, V42, P696 SHEAR NH, 1986, ANN INTERN MED, V105, P179 SHEAR NH, 1988, J CLIN INVEST, V82, P1826 VANDERVEN AJA, 1995, BRIT J CLIN PHARMACO, V38, P147 WOLKENSTEIN P, 1995, PHARMACOGENETICS, V5, P255; NR: 18; TC: 5; J9: BIOMARKERS; PG: 6; GA: VV689

Source type: Electronic(1)

Language

  • English

Subjects

  • HYDROXYLAMINE METABOLITES
  • GLUTATHIONE
  • Biotechnology & Applied Microbiology
  • N-acetyltransferase
  • sulfamethoxazole
  • hypersensitivity
  • Toxicology
  • sulphamethoxazole
  • IDIOSYNCRATIC TOXICITY
  • risk
  • cytotoxicity
  • hydroxylamine
Page range
267-272
Host Title
Biomarkers
Host Abbreviated Title
Biomarkers
Volume
1
Issue
4
ISSN
1354-750X

Department